Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995–2014

Emerging Infectious Diseases

Volumn 22, Issue 10, 2016, Pages 1712-1719

  Shaghaghi, Mohammadreza ^a,b,c   Shahmahmoodi, Shohreh ^a,d   Abolhassani, Hassan ^a,b,c   Soleyman Jahi, Saeed ^a,b   Parvaneh, Leila ^a   Mahmoudi, Sussan ^e   Chavoshzadeh, Zahra ^f   Yazdani, Reza ^b,g   Zahraei, Seyed Mohsen ^e   Ebrahimi, Mohsen ^a,h   Eslamian, Mohammad H ^a,h   Tabatabaie, Hamideh ^d   Yousefi, Maryam ^d   Kandelousi, Yaghoob M ^d   Oujaghlou, Aliasghar ^d   Rezaei, Nima ^a,b,c   Aghamohammadi, Asghar ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSAL SCIENTIFIC EDUCATION AND RESEARCH NETWORK USERN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; ORAL POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BARE LYMPHOCYTE SYNDROME; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; DISEASE SURVEILLANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLACCID PARALYSIS; GENE MUTATION; GENE SEQUENCE; HEAVY CHAIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; MALE; NIJMEGEN BREAKAGE SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTYPE; VIRUS SHEDDING; X LINKED AGAMMAGLOBULINEMIA; YOUNG ADULT; COMPLICATION; FECES; FOLLOW UP; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IRAN; ISOLATION AND PURIFICATION; MORTALITY; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; CHILD; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; IRAN; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; TREATMENT OUTCOME; VIRUS SHEDDING; YOUNG ADULT;

EID: 84988530501     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2210.151071     Document Type: Article

References (40)

1. Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. MMWR Morb Mortal Wkly Rep. 2015;64:640–6.
2. Morales M, Tangermann RH, Wassilak SG. Progress toward polio eradication—worldwide, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65:470–3. http://dx.doi.org/10.15585/mmwr.mm6518a4
3. Trimble R, Atkins J, Quigg TC, Burns CC, Wallace GS, Thomas M, et al. Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome—Texas, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:721–4.
4. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, April 2011–June 2012. MMWR Morb Mortal Wkly Rep. 2012;61:741–6.
5. Minor PD, Macadam AJ, Stone DM, Almond JW. Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals. 1993;21:357–63. http://dx.doi.org/10.1006/biol.1993.1096
6. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635. http://dx.doi.org/10.1146/annurev.micro.58.030603.123625
7. Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, et al. Persistence of vaccine-derived polioviruses among immuno-deficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188:1845–52. http://dx.doi.org/10.1086/379791
8. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses— worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:950–4.
9. Shaghaghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H, et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest. 2014;43:292–8. http://dx.doi.org/10.3109/08820139.2013.859156
10. Shahmahmoodi S, Mamishi S, Aghamohammadi A, Aghazadeh N, Tabatabaie H, Gooya MM, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995–2008. Emerg Infect Dis. 2010;16:1133–6. http://dx.doi.org/10.3201/eid1607.091606
11. Shahmahmoodi S, Parvaneh N, Burns C, Asghar H, Mamishi S, Tabatabaie H, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res. 2008;137:168–72. http://dx.doi.org/10.1016/j.virusres.2008.07.006
12. Parvaneh N, Shahmahmoudi S, Tabatabai H, Zahraei M, Mousavi T, Esteghamati AR, et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J Clin Virol. 2007;39:145–8. http://dx.doi.org/10.1016/j.jcv.2007.04.002
13. Mamishi S, Shahmahmoudi S, Tabatabaie H, Teimourian S, Pourakbari B, Gheisari Y, et al. Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. Eur J Pediatr. 2008;167:1335–8. http://dx.doi.org/10.1007/s00431-008-0674-5
14. World Health Organization. Polio laboratory manual. 4th ed. WHO/IVB/04.10, 2004 [cited 2016 Jun 17]. http://apps.who.int/immunization_monitoring/laboratory_polio_resources/en/index.html
15. Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014;34:478–90. http://dx.doi.org/10.1007/s10875-014-0001-z
16. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26:519–32. http://dx.doi.org/10.1007/s10875-006-9047-x
17. Buckley RH. Evaluation of suspected immunodeficiency. In: Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. Philadelphia: Elsevier/Saunders; 2012. p. 715–22.
18. Diop OM, Burns CC, Wassilak SG, Kew OM; Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2012–December 2013. MMWR Morb Mortal Wkly Rep. 2014;63:242–8.
19. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2006–August 2007. MMWR Morb Mortal Wkly Rep. 2007;56:996–1001.
20. Racaniello VR, Ren R. Poliovirus biology and pathogenesis. Curr Top Microbiol Immunol. 1996;206:305–25. http://dx.doi.org/10.1007/978-3-642-85208-4_15
21. Al-Herz W, Moussa MA. Survival and predictors of death among primary immunodeficient patients: a registry-based study. J Clin Immunol. 2012;32:467–73. http://dx.doi.org/10.1007/s10875-011-9636-1
22. Robbins FC. Polio. Rochester (NY): University of Rochester Press; 1999.
23. Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis. 2009;199:391–7. http://dx.doi.org/10.1086/596052
24. Driss N, Ben-Mustapha I, Mellouli F, Ben Yahia A, Touzi H, Bejaoui M, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol. 2012;19:1684–9. http://dx.doi.org/10.1128/CVI.00293-12
25. Avellón A, Cabrerizo M, De Miguel T, Pérez-Breña P, Tenorio A, Pérez JL, et al. Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain. Emerg Infect Dis. 2008;14:1807–9. http://dx.doi.org/10.3201/eid1411.080517
26. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol. 2000;74:7381–90. http://dx.doi.org/10.1128/JVI.74.16.7381-7390.2000
27. Odoom JK, Yunus Z, Dunn G, Minor PD, Martín J. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J Virol. 2008;82:9179–90. http://dx.doi.org/10.1128/JVI.00468-08
28. Martín J, Odoom K, Tuite G, Dunn G, Hopewell N, Cooper G, et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J Virol. 2004;78:13839–47. http://dx.doi.org/10.1128/JVI.78.24.13839-13847.2004
29. van der Sanden S, Pallansch MA, Van De Kassteele J, El-Sayed N, Sutter RW, Koopmans M, et al. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol. 2009;83:8693–704. http://dx.doi.org/10.1128/JVI.02388-08
30. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1002–6.
31. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009–March 2011. MMWR Morb Mortal Wkly Rep. 2011;60:846–50.
32. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep. 2006;55:1093–7.
33. DeVries AS, Harper J, Murray A, Lexau C, Bahta L, Christensen J, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med. 2011;364:2316–23. http://dx.doi.org/10.1056/NEJMoa1008677
34. Li L, Ivanova O, Driss N, Tiongco-Recto M, da Silva R, Shahmahmoodi S, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis. 2014;210(Suppl 1):S368–72. http://dx.doi.org/10.1093/infdis/jiu065
35. Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenla MA, da Silva E, Khan AJ, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ. 2004;82:3–8.
36. de Silva R, Gunasena S, Ratnayake D, Wickremesinghe GD, Kumarasiri CD, Pushpakumara BA, et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine. 2012;30:7561–5. http://dx.doi.org/10.1016/j.vaccine.2012.10.035
37. Blomqvist S, Savolainen C, Laine P, Hirttiö P, Lamminsalo E, Penttilä E, et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol. 2004;78:4876–83. http://dx.doi.org/10.1128/JVI.78.9.4876-4883.2004
38. Roivainen M, Blomqvist S, Al-Hello H, Paananen A, Delpeyroux F, Kuusi M, et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill. 2010;15:pii: 19566.
39. Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, Halmut T, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol. 2000;38:3729–34.
40. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med. 2000;343:767–73. http://dx.doi.org/10.1056/NEJM200009143431103